The double whammy—Opsoclonus–Myoclonus–Ataxia syndrome and COVID-19: A case report

Vijayaraghavan, Revathy; Paramanandam, Vijayashankar; Sankaranarayanan, Muthukani; Kankanala, Madhuri; Bindu, PendemHima; Safinaaz,; Alex, NeetuMariam

doi:10.4103/aian.aian_1110_21

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the majority of cases, symptomatic treatment has been combined with immunotherapy, and in these cases a significant improvement was observed between three days after the steroids administration [42,46] and three months after the onset of treatment. There have also been reports of two patients who did not improve with steroids, but were then administered second-line IVIG or IVIG with rituximab with recovery [18,39]. Treatment with corticosteroids seems to be equally effective, but significantly cheaper and more readily available than IVIG therapy.…”

Section: Ataxia/myoclonus/opsoclonus Syndromementioning

confidence: 99%

Hyperkinetic movement disorders following SARS-CoV-2 infection and vaccination — an update

Przytuła¹,

Sławek

2023

Neurol Neurochir Pol.

View full text Add to dashboard Cite

The aim of this review was to summarise current knowledge regarding hyperkinetic movement disorders related to SARS-CoV-2 infection and vaccination in terms of phenomenology, epidemiology, pathogenesis and treatment. After a thorough review of the PubMed and Google Scholar databases (2020-2022), we identified myoclonus and ataxia sometimes accompanied by opsoclonus (AMS) as the two most frequent COVID-19 sequelae, with chorea, tremor and dystonia being very rare. The pathogenesis seems to be variable, but in the majority of AMS cases it was autoimmunological, with good response and recovery after corticosteroids or intravenous immunoglobulins infusions. Vaccination may be complicated by hyperkinetic movement disorders (e.g. tremor, dystonia), but this is very rare. Patients with Deep Brain Simulation depletion should not be postponed due to lockdowns as this may result in fatal outcomes.

show abstract

Section: Ataxia/myoclonus/opsoclonus Syndromementioning

confidence: 99%

Hyperkinetic movement disorders following SARS-CoV-2 infection and vaccination — an update

Przytuła¹,

Sławek

2023

Neurol Neurochir Pol.

View full text Add to dashboard Cite

show abstract

Opsoclonus-Myoclonus-Ataxia Syndrome Due to Covid-19

Adamaszek,

Langner,

Mehrholz

et al. 2023

Cerebellum

View full text Add to dashboard Cite

Opsoclonus myoclonus syndrome (OMS) is a rare neurological encephalopathic entity associated with non-speci c infections or cancer processes that has been occasionally described in the setting of SARS-CoV-2 infection. We report a case of a 53-year-old man with SARS-CoV-2 infection, who developed clinical features of opsoclonus-myoclonus syndrome. Of particular note, cerebrospinal uid analysis (CSF) analysis revealed the production of myelin oligodendrocyte glycoprotein (MOG) antibodies, suggesting an underlying neuroimmunological mechanism associated with infection with the novel SARS-CoV-2 virus. Full TextIn addition to the primary medical and epidemiological challenges, the SARS-CoV-2 pandemic has triggered a vivid research activity on the organic dysfunctions associated with the virus known as Covid-19 and numerous investigations have been undertaken aiming to capture and re ne the pathogenetic

show abstract

The double whammy—Opsoclonus–Myoclonus–Ataxia syndrome and COVID-19: A case report

Cited by 2 publications

References 5 publications

Hyperkinetic movement disorders following SARS-CoV-2 infection and vaccination — an update

Hyperkinetic movement disorders following SARS-CoV-2 infection and vaccination — an update

Opsoclonus-Myoclonus-Ataxia Syndrome Due to Covid-19

Contact Info

Product

Resources

About